“Compensation, an operation to dissect”
Jean-François Quievy, managing partner of the firm, has published a new article on the various aspects of the compensation mechanism in contract law, disseminated on actu-juridique.fr and soon to be published in the Petites Affiches.
The full article is accessible by following this link: “Compensation, an operation to dissect”
Latest news
April 30, 2024
EQA participated to the “English Law Day” in Istanbul
EQA had the honor of participating in the English Law Day in Istanbul on April 16, 2024, an event bringing together legal professionals from around the world. During this event, Etienne Epron spoke on a panel dedicated to the Impact of sanctions on trade, transactions, contracts, and disputes. We wish to express our sincere gratitude… Continue reading EQA participated to the “English Law Day” in Istanbul
April 29, 2024
Margot De Almeida Lopes joins EQA
We are pleased to welcome Margot De Almeida Lopes as an associate in the M&A / Corporate Law & Tax departments. Margot holds a Master II in Internal and International Contract Law from the University of Paris-Saclay as well as a Master I in Business Law. We extend our best wishes for her success within… Continue reading Margot De Almeida Lopes joins EQA
November 15, 2023
Épron Quievy & Associé advised Proclus SAS within its structuring and its first fundraising
On the occasion of its first round of financing completed in November 2023, Epron Quievy & Associés advised Proclus SAS, a leading independent French player in the reuse of professional electrical equipment. Proclus SAS is a fresh company set up in 2022 addressing the market with removed, requalified and reconditioned used technical equipment. Within its… Continue reading Épron Quievy & Associé advised Proclus SAS within its structuring and its first fundraising
October 23, 2023
Épron Quievy & Associé advised Paltech SAS within it’s second fundraising
After a first fundraising in 2021, Paltech SAS closed in October 2023 a new round of more than one million euros fully subscribed by private investors. Founded by doctors Réginald Allouche and Charles-Henri Malbert in 2021, Paltech SAS is an innovative company dedicated to the research for a curative treatment for type 2 diabetes.